Magí Farré
Clinical Pharmacologist
Papers
Trials
Key Impact
A prominent European clinical pharmacologist whose human experimental studies and evidence syntheses have substantially advanced understanding of the acute effects, safety profile and therapeutic potential of classical and novel psychedelic compounds.
Background & Research
Magí Farré is a clinical pharmacologist based in Spain who specialises in human experimental psychopharmacology and clinical research on classical psychedelics and novel psychoactive substances. His research portfolio spans controlled and observational human pharmacology studies (including work on 2C‑B, mephedrone and MDMA), translational investigations of ayahuasca‑assisted interventions, and genetic moderators of drug response. He works at the interface of pharmacology, psychiatry and addiction medicine and is known for rigorous safety monitoring and careful phenotyping in acute drug challenge studies.
Farré's major contributions include detailed human pharmacology characterisations of 2C‑B and mephedrone, comparative studies situating newer stimulants against MDMA, and clinical investigations exploring psychedelic‑assisted approaches for bereavement and mood disorders. He has also co‑authored systematic reviews and policy‑oriented evidence briefs that contextualise historical and contemporary findings on LSD, ayahuasca and MDMA, and has participated in scholarly debate about risks such as psychedelic‑associated psychosis. Collectively his work has informed safety standards, clinical trial design and translational research agendas in psychedelic medicine.